文献速递心脑血管急症重症综合管理与镇静镇痛

33°C或36°C靶向温度管理在大脑中动脉闭塞缺血性卒中大鼠模型中产生等效神经保护作用

Targeted Temperature Management at 33°C or 36°C Produces Equivalent Neuroprotective Effects in the Middle Cerebral Artery Occlusion Rat Model of Ischemic Stroke.
PubMed 文献 · Shock · 2018-01-01
一句话结论大鼠大脑中动脉闭塞模型中,33°C与36°C靶向温度管理在缩小梗死体积、减轻炎症和改善神经功能方面效果相当。

该研究在大鼠大脑中动脉闭塞(MCAO)缺血性卒中模型中,比较33°C与36°C靶向温度管理(TTM)的神经保护效果。大鼠随机分为MCAO组、MCAO+33°C TTM组、MCAO+36°C TTM组和假手术组,MCAO持续3小时(行为测试)或4小时(生化分析)。两种TTM方案均产生相当的梗死体积缩小、等同减轻缺血后脑内高迁移率族蛋白B1的细胞外释放、均阻止缺血半暗带区主要促炎细胞因子肿瘤坏死因子-α的mRNA诱导,并在再灌注开始后21小时的行为测试中产生相似的神经功能改善。

要点

  • 大鼠MCAO模型中,33°C与36°C TTM均产生相当的梗死体积缩小。
  • 两种TTM均等同减轻缺血后脑内高迁移率族蛋白B1的细胞外释放。
  • 两种TTM均阻止缺血半暗带区肿瘤坏死因子-α的mRNA诱导。
  • 再灌注开始后21小时行为测试显示,两种TTM产生相似的神经功能改善。
  • 大鼠MCAO模型数据提示36°C TTM对改善急性缺血性卒中患者临床结局有良好治疗潜力。

适用人群与场景

  • 大鼠大脑中动脉闭塞(MCAO)缺血性卒中模型;MCAO持续3小时用于行为测试,持续4小时用于其他生化分析。

处置流程与药物剂量

  • 大鼠随机分为MCAO组、MCAO+33°C TTM组、MCAO+36°C TTM组和假手术组;除假手术组外均接受MCAO。
  • TTM方案为33°C或36°C。

研究设计与关键结果

  • 研究类型:大鼠MCAO缺血性卒中模型实验;大鼠随机分为MCAO组、MCAO+33°C TTM组、MCAO+36°C TTM组和假手术组。
  • 33°C与36°C TTM均产生MCAO供血区梗死体积的相当缩小。
  • 33°C与36°C TTM均等同减轻缺血后脑内高迁移率族蛋白B1的细胞外释放。
  • 两种TTM条件均阻止缺血半暗带区肿瘤坏死因子-α的mRNA诱导。
  • 再灌注开始后21小时的行为测试显示,两种TTM方案产生相似的神经功能改善。

证据类型、等级与局限

  • 证据类型:大鼠MCAO模型动物实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,大鼠MCAO模型数据提示36°C TTM对改善急性缺血性卒中患者临床结局有良好治疗潜力。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Targeted temperature management (TTM, 32°C to 36°C) is one of the most successful achievements in modern resuscitation medicine. It has become standard treatment for survivors of sudden cardiac arrest to minimize secondary brain damage. TTM at 36°C is just as effective as TTM at 33°C and is actually preferred because it reduces adverse TTM-associated effects. TTM also likely has direct neuroprotective effects in ischemic brains in danger of stroke. It remains unclear, however, whether higher temperature TTM is equally effective in protecting the brain from the effects of stroke. Here, we asked whether TTM at 36°C is as effective as TTM at 33°C in improving outcomes in a middle cerebral artery occlusion (MCAO) model of ischemic stroke. After dividing rats randomly into MCAO, MCAO+33°C TTM, MCAO+36°C TTM, and sham groups, we subjected all of them except for the sham group to MCAO for 3 h (for the behavioral tests) or 4 h (for all other biochemical analyses). We found TTM protocols at both 33°C and 36°C to produce comparable reductions of infarct volumes in the MCAO territory and equally attenuate the extracellular release of high mobility group box 1 in postischemic brains. Both the TTM conditions prevent the mRNA induction of a major pro-inflammatory cytokine, tissue necrosis factor-α, in the ischemic penumbra region. Finally, both the TTM protocols produce similar improvements in neurological outcomes in rats, as measured by a battery of behavior tests 21 h after the start of reperfusion. These data acquired in a rat MCAO model suggest TTM at 36°C has excellent therapeutic potential for improving clinical outcomes for patients with acute ischemic stroke.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Lee JH, Lim J, Chung YE, et al. Targeted Temperature Management at 33°C or 36°C Produces Equivalent Neuroprotective Effects in the Middle Cerebral Artery Occlusion Rat Model of Ischemic Stroke. Shock. 2018. PMID: 29337840. doi:10.1097/SHK.0000000000001106

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。